MOUNTAIN VIEW, Calif., Dec. 13, 2022 /PRNewswire/ — Lacework®, the data-driven cloud security company, today announced the appointment of Niels Provos as the company's first Head of...

As we approach the end of the year, it’s time to sit back with a fresh cup of tea, look out the window...

KUALA LUMPUR, Nov 29, 2022 - (ACN Newswire) - Corinium's Chief Information Security Officer (CISO) Malaysia gathers the region's leading infosec executives to share insights on transformative leadership,...

- Over 50 million passwords stolen in 7 months of 2022- Underground market value of stolen logs and compromised card details around US$5.8 million-...

HONG KONG, Mar 7, 2022 - (ACN Newswire) - IWS Group Holdings Limited ("IWS Group" or the "Group"), the largest security services provider in the public sector in Hong Kong(1) and an established facility services provider, has successfully transferred from GEM to Main Board of The Stock Exchange of Hong Kong Limited (the "HKEX") today. The Group commenced trading under the stock code of 6663.
About IWS Group Holdings Limited
IWS Group Holdings Limited is the largest security services provider in the public sector in Hong Kong(1) and an established facility services provider specialising in the provision of security services and facility management services across public and private sectors in Hong Kong. The Group has over 10 years of experience in providing security services at railway stations and facilities, sea, land and railway immigration control points and public amenities as well as crowd coordination and management services at various large-scale events and emergency and critical incidents in Hong Kong.

(1) Frost & Sullivan, in terms of revenue in 2020

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comIWS Group Holdings Limited ("IWS Group" or the "Group"), the largest security services provider in the public sector in Hong Kong and an established facility services provider, has successfully transferred from GEM to Main Board of The Stock Exchange of Hong Kong Limited (the "HKEX") today.

Software collects, analyzes, and interprets potential zero-day threats in real time using inline deep learning.

Attivo Networks ADSecure-DC solution joins the company’s existing suite of Active Directory protection products.

SYDNEY, Mar 2, 2022 - (ACN Newswire) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.
Avance Clinical's CEO Yvonne Lungershausen said: "We continue to offer a hybrid working environment for our team however, they are increasingly wanting more in-office face-to-face time with colleagues and clients - while still having the flexibility of working remotely".

"Avance is continuing to experience significant growth facilitating our expansion into North Sydney with new offices to accommodate our growing team," she said.

Check for our latest positions open and join our Sydney team here. https://www.avancecro.com/careers/

Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.

"With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.

"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.

Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.

Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/

For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.

Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.

Media Contacts:
Avance Clinical
Chris Thompson
[email protected]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAvance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.

HONG KONG, Feb 23, 2022 - (ACN Newswire) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today, under the stock code of 2157 and in board lot of 1,000 H shares each.

The share price of the Company closed at HK$7.14 per H share, with an intra-day high of HK$7.34 per H share. A total of approximately 15.8 million H shares were traded, with an aggregate turnover of approximately HK$112 million.

Lepu Biopharma is listed on the main board of HKEX, with 126,876,000 H shares being offered globally, including 12,688,000 Hong Kong Offer Shares, 114,188,000 International Placing Shares. The net proceeds received are estimated at approximately HK$804.2 million from the Global Offering, after deduction of underwriting fees, commissions and other estimated expenses payable by the Company in connection with the Global Offering. The net proceeds are intended for funding the core products, funding the other key clinical-stage drug candidates and the key pre-clinical drug candidates, acquiring potential technologies and assets and expand our pipeline of drug candidates, including discovery of new drug candidates and business development activities and to fulfill the continuous payment obligation under the acquisition of HX008 from HanX, and general corporate purposes.

Lepu Biopharma has three synergistic core technology platforms around its pipeline specializing in ADC technology, antibody discovery and advanced process and analytical development. The company also advances the clinical development of its candidates including ADC candidates, oncolytic virus candidates and combination therapies, plans to stay focused on the development of innovative products, create a pipeline for novel therapies, design and develop innovative products and build advanced technology platforms.

While Lepu Biopharma advancing its drug candidates, it has mapped out and is implementing the manufacturing and commercialization strategies. Company commenced the operation of a 2,000L GMP-compliant antibody production line in Beijing in 2019 in support of clinical trials for the antibody products. It is building a production line for oncolytic virus drugs in Beijing with a designed capacity of 200L, as well as a biologics manufacturing center in Shanghai Biotech Park, including a production line with a designed capacity of 12,000L initially, coupled with laboratories and manufacturing facilities, and one production line with capacity of 6,000L under construction.

The Founder, Chairman and Executive Director of Lepu Biopharma Co., Ltd. Dr. Pu Zhongjie said, "Today, we are very delighted to witness Lepu Biopharma to be officially listed on the Hong Kong Stock Exchange. This is an important milestone in our history of development as well as a starting point of our new journey. We sincerely appreciated the long-term trust and cooperation from customers and shareholders. We would also like to thank our partners, the Hong Kong Stock Exchange and the Securities and Futures Commission for all the great support. With solid R&D capabilities, advanced development platforms and comprehensive pipeline, we will seize the future trend of the whole industry, strengthen our position in the market with our competitive advantages and create greater value for shareholders and investors."

About Lepu Biopharma Co., Ltd.

Lepu Biopharma was incorporated in 2018 and is a biopharmaceutical company focusing on oncology therapeutics. The Company has designed pipeline with a range of oncology products. As of [the Latest Practicable Date], the Company had pipeline including eight clinical-stage drug candidates, three pre-clinical drug candidates and three clinical-stage combination therapies of the candidates in the pipeline. In addition, the Company focus on the development of innovative drugs including ADC and oncolytic virus. According to Frost & Sullivan, the Company house the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates. As of [the Latest Practicable Date], the Company had initiated 28 clinical trials, among which three had entered registration trial phase and two were ongoing in the U.S. In terms of patents, as of [the Latest Practicable Date], Company had 11 issued patents in China, 20 in the U.S., nine in Japan, seven in the European Union and one in each of South Korea, Australia, Chile, India, Colombia, Indonesia, New Zealand and Israel, and 74 pending patent applications, consisting of 15 in Mainland China and 59 in overseas jurisdictions such as the U.S., Japan, India, South Korea, Australia, Israel, India and the European Union. Patentportfolio of the Company spans across mAb structure, targeted epitope, CMC, usage, biopharmaceutical formulation and indications.

For more information on Lepu Biopharma, please visit the website https://www.lepubiopharma.com/


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today

HONG KONG, Feb 10, 2022 - (ACN Newswire) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

Lepu Biopharma plans to offer 126,876,000H shares (subject to the Over-allotment Option), of which 114,188,000 H shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing 90% of the initial offer shares; the remaining 12,688,000 H shares will be Hong Kong Offer Shares (subject to reallocation), representing 10% of the initial offer shares. Offer Price is between HK$6.87 and HK$7.38 per Offer H Share. Lepu Biopharma will open for Hong Kong Public Offering in Hong Kong at 9 a.m., 10 February 2022 (Thursday), and close at 12:00 noon, 15 February 2022 (Tuesday). Dealings in shares of Lepu Biopharma on the Main Board of the Hong Kong Stock Exchange is expected to commence on 23 February 2022 (Wednesday). The shares will be traded in board lot of 1,000 shares each. The Company's stock code is 2157.

-- China International Capital Corporation Hong Kong Securities Limited and Morgan Stanley Asia Limited are the Joint Sponsors and Joint Global Coordinators.

-- China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited (exclusively for Hong Kong Offer Shares), Morgan Stanley & Co. International plc (exclusively for International Offer Shares), Haitong International Securities Company Limited, Huatai Financial Holdings (Hong Kong) Limited, China Galaxy International Securities (Hong Kong) Co., Limited and Valuable Capital Ltd. are the Joint Bookrunners.

-- China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited (exclusively for Hong Kong Offer Shares), Morgan Stanley & Co. International plc (exclusively for International Offer Shares), Haitong International Securities Company Limited, Huatai Financial Holdings (Hong Kong) Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Valuable Capital Ltd. and Tiger Brokers (HK) Global Limited (exclusively for International Offer Shares) are the Joint Lead Managers.

Lepu Biopharma was incorporated in 2018 and is a biopharmaceutical company focusing on oncology therapeutics. The Company has designed pipeline with a range of oncology products. As of the Latest Practicable Date, the Company had pipeline including eight clinical-stage drug candidates, three pre-clinical drug candidates and three clinical-stage combination therapies of the candidates in the pipeline. The product pipeline of Lepu Biopharma features broad-spectrum anti-tumor drugs, including primarily the anti-PD-1 antibody candidate, as the backbone, and a dual focus on ADC and oncolytic virus drug candidates, maximizing synergies in both drug efficacy and commercialization and enabling company to expand indications and addressable market. The Company takes Anti-PD-1 antibody candidate as the cornerstone of its immunotherapies, advances the research and development of related products. The Company filed an NDA of HX008 in melanoma in June 2021 with the NMPA, and filed an NDA of HX008 in MSI-H/dMMR solid tumors in October 2021 with the NMPA. In addition, the Company focus on the development of innovative drugs including ADC and oncolytic virus. According to Frost & Sullivan, the Company house the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates. The comprehensive ADC and oncolytic virus pipeline of company creates synergies and maximizes its competitive strength in commercialization. As of the Latest Practicable Date, company had initiated 28 clinical trials, among which three had entered registration trial phase and two were ongoing in the U.S.

Core Product with Encouraging Clinical Trial Results and Advance R&D Smoothly

The major pipeline assets of Lepu Biopharma consist of four core products, namely, MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates.

Among core products, MRG003 and MRG002 are ADC drug candidates, MRG003 is the most advanced EGFR-targeted ADC in clinical-stage development in China and has the potential to seize market opportunities. The Company is conducting Phase II clinical trials of MRG003 in recurrent or metastatic advanced HNSCC, advanced NSCLC, BTC and NPC in China, and expects to initiate clinical trials in recurrent or metastatic advanced HNSCC in the U.S. and expand MRG003 indications based on the clinical data obtained, further expanding the overall addressable market with the aim of achieving international commercialization with MRG003.

MRG002 is an innovative HER2-targeted ADC. Company's pre-clinical studies revealed better efficacy as compared to T-DM1 (trastuzumab emtansine) in multiple Herceptin-resistant HER2 over- and low-expressing PDX models of the gastric cancer and breast cancer. The Company had initiated Phase II clinical trials of MRG002 in HER2 low-expressing and over-expressing breast cancer, UC (urothelial cancer) and HER2 over-expressing BTC. For HER2 over-expressing breast cancer, the Company had obtained approval from the NMPA of registration trial.

HX008 and LP002 are anti-PD-1/anti-PD-L1 drug candidates, HX008 is a humanized antagonist mAb to human PD-1, which demonstrated efficacy and a good safety profile in the completed Phase Ia clinical trial in solid tumors. As of the Latest Practicable Date, the Company was also in the process of conducting a Phase II clinical trial of HX008 in NMIBC and a Phase III clinical trial of HX008 in the second-line gastric cancer. LP002 is a humanized mAb against PD-L1, which has shown a favorable safety profile in a Phase Ia clinical study in advanced solid tumors. Lepu Biopharma are in the process of a cohort expansion trial in advanced digestive system cancer and have completed patient enrollment and entered the follow-up period for Phase II clinical trials in ES-SCLC in China.

Core Technology Platforms to Buttress Products

Lepu Biopharma has demonstrated capabilities in the development of innovative drugs spanning across early-stage molecular target identification and validation, pre-clinical development and CMC development. The Company has three synergistic core technology platforms around its pipeline specializing in ADC technology, antibody discovery and advanced process and analytical development.

The Company has fully integrated ADC technology platform covering discovery, process and analytical development and manufacturing, is able to design and create new molecules with innovative mechanisms and utilize cutting-edge technology, such as GlycoConnect(TM) site-specific conjugation technology. It has, among others, cutting-edge ADC technologies including sophisticated DAR control technology, advanced ADC conjugation technology, identification and validation of early-stage molecular targets, ADC process development and a well-established quality analysis system.

The Company has constructed a full human naive antibody library of 1011 scale, the platform reduces the reliance on animal immune systems to produce antibodies, and significantly shorten the development period of innovative drug candidates to four to six weeks compared to the traditional hybridoma technology. The Company has also constructed a trispecific antibody T cell engager platform by utilizing protein binding domains, such as nanobodies and scFv, to augment T cells' response to solid tumors.

Lepu Biophamra has an advanced process and analytical development platform for antibodies and ADCs. The Company has impl emented a comprehensive set of quality analysis methods and inspection technology to assess and control the product quality in the course of process and analytical development and production to fulfill the requirements for registration, in order to ensure a standardized process and analytical development and quality control.

Intellectual Property Promotes the Sustainable Development of Drugs
Implement Manufacturing and Commercialization Layout

Intellectual property is pivotal to the sustainable development and commercialization of drugs, the Company endeavors to ensure global full-life-cycle IP protection for drug candidates. As of the Latest Practicable Date, Company had 11 issued patents in China, 20 in the U.S., nine in Japan, seven in the European Union and one in each of South Korea, Australia, Chile, India, Colombia, Indonesia, New Zealand and Israel, and 74 pending patent applications, consisting of 15 in Mainland China and 59 in overseas jurisdictions such as the U.S., Japan, India, South Korea, Australia, Israel, and the European Union. Our patent portfolio spans across mAb structure, targeted epitope, CMC, usage, biopharmaceutical formulation and indications.

While Lepu Biopharma advancing its drug candidates, it has mapped out and is implementing the manufacturing and commercialization strategies. Company commenced the operation of a 2,000L GMP-compliant antibody production line in Beijing in 2019 in support of clinical trials for the antibody products, it is building a production line for oncolytic virus drugs in Beijing with a designed capacity of 200L, as well as a biologics manufacturing center in Shanghai Biotech Park, including production line with a designed capacity of 12,000L initially, coupled with laboratories and manufacturing facilities, and one production line with capacity of 6,000L under construction. The Company is building marketing forces in China and seeking partnership opportunities to support international expansion and commercialization.

Expedite Innovative Drugs Development
Advance Pipeline and Technology Platforms Construction

Lepu Biopharma strives to expedites immune checkpoint inhibitor therapy development, aims to achieve expedited and adequate market coverage of HX008 through both medical institutions and direct-to-patients distribution channels by leveraging the broad spectrum of indications covered by MSI-H/dMMR solid tumors. The Company expects to establish effective sales channels and strengthen the commercialization capabilities through the commercialization of HX008, which would also benefit its efforts to commercialize other drug candidates. The Company also plans to seek strategic partnerships with preeminent pharmaceutical companies internationally to maximize the clinical and commercial value of its immune checkpoint inhibitors.

Lepu Biopharma advances the clinical development of its candidates including ADC candidates, oncolytic virus candidates and combination therapies, plans to stay focused on the development of innovative products, create a pipeline for novel therapies, design and develop innovative products and build advanced technology platforms. In addition, the Company is committed to strengthening its overseas business development of pipeline, enhancing the brand awareness and continuously exploring the commercial value of its products and technology in the international market, and will make efforts to pursue out-licensing partnership opportunities in overseas markets. Furthermore, to meet the commercialization demand, the Company will expand GMP-compliant manufacturing facilities to increase capacity and enhance product quality.

The Founder, Chairman and Executive Director of Lepu Biopharma Co., Ltd. Dr. Pu Zhongjie said, "Since our inception, Lepu Biopharma focuses on the development of innovative drugs, the design and well-establishment of pipeline, we have established an integrated end-to-end platform across drug discovery, clinical development and CMC and GMP-compliant manufacturing. As an innovation-driven biopharmaceutical company leveraging an internationally integrated research and development system, we are committed to fulfilling current medical needs. Lepu Biopharma has solid R&D capabilities, advanced development platforms and comprehensive pipeline, we will the hold future trend and of the whole industry, use our competitive strengths to keep Lepu Biopharma's status in the market and maxmize the created value for shareholders and investors."



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

In a recent performance test, cybersecurity provider Link11 was benchmarked against leading international security vendors and emerged as the winner. The study by Frost & Sullivan emphasized the importance of precise detection and speed in mitigating DDoS (Distributed Denial of Service) attacks.

- The acquisition bolsters HMI Group's offering of complete one-stop healthcare services and capabilities to patients in Singapore and the region - The partnership strengthens HMI Group and EEC's market position in Southeast Asia, and positions HMI Group for continued growth, synergies, and expansion

Singapore, Jan 24, 2022 - (ACN Newswire) - Health Management International Pte Ltd (HMI Group), a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia, has acquired a majority stake in Eagle Eye Centre Pte Ltd (EEC), the largest private ophthalmology chain in Singapore. "With our investment, we will partner with EEC and work closely with the EEC doctors to grow the business locally and in the region," said Ms Chin Wei Jia, Group Chief Executive Officer of HMI Group. "This is a significant step in expanding HMI Group's portfolio into the specialist medical services as we strive to provide one-stop healthcare services both within and outside of hospitals." Founded in 2006, EEC started out as a one-stop specialist eye care facility, and was amongst the first to offer comprehensive ophthalmic care with services in all eye subspecialties under one roof. Today, EEC operates a chain of seven ophthalmology centres in Singapore together with 17 resident eye specialists. EEC offers a full suite of ophthalmic subspecialties including Cornea and Anterior Segment; Ocular Immunology and Uveitis; Cataract; Refractive Surgery; Glaucoma; Medical and surgical Retina; Neuro-Ophthalmology; Paediatrics and Strabismus; and Oculoplastic. Delivering convenience and value The EEC acquisition complements the Group's Singapore strategy, which focuses on providing quality and patient-centred healthcare services outside of hospitals that are convenient and delivers value. Furthermore, it will accelerate HMI Group's journey to capture the growing global trend of day surgery procedures, especially in developed markets, as medical skills and technology continue to advance. In Singapore, about 50% of surgical procedures can be performed in day surgery setting. "With HMI Group's expertise and reach in the region, we will continue to enhance access to high quality healthcare services for the people we serve. Through our investments in non-hospital settings, we are better prepared to deliver care in the future of health. HMI Group has a unique opportunity to use the momentum for change created by the COVID-19 crisis to accelerate the transformation of outpatient care," Ms Chin said. "We will also have the collective experience and extensive track record of Dr Julian Theng, Dr Lim Wee Kiak, and EEC's team of highly skilled sub-specialised ophthalmologists, to provide comprehensive optometric and ophthalmic care. We look forward to supporting EEC's growth ambitions and are excited to welcome the team into the HMI family." Expanding into specialist eye centres also enhances HMI Group's portfolio of primary care clinics and ambulatory care centres in Singapore. EEC recently built operating theatres and day procedure suites in King Albert Park and Royal Square Novena to perform common day surgery procedures such as Cataract and LASIK procedures outside of a hospital setting. The EEC acquisition is HMI Group's second in 2021. In September, HMI Group acquired a majority stake in OneCare Medical, a chain of 25 primary care clinics in Singapore. Through organic growth and the 2 new acquisitions, HMI Group's EBITDA has grown about 70% since HMI Group de-listed in December 2019 in a management buy-out together with EQT, a global investment firm, to now become one of the largest privately held healthcare providers in Southeast Asia. "Joining HMI Group presents a strategic opportunity for us to extend our ophthalmic services not just locally but regionally. We are thrilled to have found a purpose-driven, like-minded partner in HMI Group. With a common heart in a patient-centric approach to healthcare, while trusting us to continue leading in the ophthalmic medical management of EEC, our collective aim is to make a positive impact in our communities as we grow together," said Dr Julian Theng, Group Chairman and Medical Director of EEC. "We are optimistic about the further development of our business while tapping on synergies across the Group to better serve our patients." About Health Management International Pte Ltd Health Management International Pte Ltd ("HMI" or the "Group") is a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Group owns and operates two tertiary hospitals in Malaysia. In Singapore, the Group owns and operates a healthcare training centre, a primary care clinic chain with 25 locations, and Singapore's first private one-stop ambulatory care centre. The Group also has a network of representative offices in Indonesia, Malaysia and Singapore. Established in 1994, Mahkota Medical Centre ("Mahkota") is HMI Group's flagship hospital located in the heart of Malacca and is the first JCI-accredited hospital in Malacca. The 340-bed hospital is the largest private tertiary hospital in South Malaysia, and is the first and only hospital in Malacca to offer nuclear medicine and kidney transplant services. Mahkota sees close to 100,000 international patients per year and was named the "Malaysia Medical Tourism Hospital of the Year" by Frost & Sullivan in 2015 and 2016. The Group's second hospital, Regency Specialist Hospital ("Regency") was launched in 2009 and is one of the fastest growing private tertiary hospitals in Malaysia located in the state of Johor. The 218-bed Regency is the only private hospital in Malaysia with a 24-hour Emergency & Trauma Centre, providing round the clock specialist attention and medical care to both local and international patients. Regency is in the midst of building a major hospital extension block to increase capacity up to 500 beds. The Group holds a majority stake in StarMed Specialist Centre ("StarMed"), a one-stop day-surgery and multidisciplinary medical centre that offers quality clinical services at competitive private sector prices. The Group also holds a majority stake in OneCare Medical, a fast-growing primary care clinic chain with 25 clinics across Singapore. HMI Group's healthcare training centre, the HMI Institute of Health Sciences, is the Group's Social Enterprise arm and a SkillsFuture Singapore accredited Continuing Education and Training Centre for the healthcare support sector. For more information, please refer to www.hmi.com.sg. About Eagle Eye Centre Pte Ltd Established in 2006, Eagle Eye Centre Pte Ltd ("EEC") is the largest private ophthalmology chain in Singapore. EEC operates a chain of 7 ophthalmology centres in Singapore together with 17 resident eye specialists. EEC offers a full suite of ophthalmic subspecialties including Cornea & Anterior Segment, Ocular Immunology & Uveitis, Cataract, Refractive Surgery, Glaucoma, Retina, Neuro-Ophthalmology, Paediatrics & Strabismus and Oculoplastics. EEC is committed to deliver quality eye care treatment at affordable prices that can best serve the mass community and constantly invests in technology to keep up with its pace. EEC was recognised as the Ophthalmology Service Provider of the Year by Global Health Awards for the past 5 consecutive years. For more information, please refer to www.eagleeyecentre.com.sg. Contact: Chi-an Chang, Director, Financial PR [email protected]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comHealth Management International Pte Ltd (HMI Group), a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia, has acquired a majority stake in Eagle Eye Centre Pte Ltd (EEC), the largest private ophthalmology chain in Singapore.